- Home
- ARVN vs NUTX Comparison
ARVN vs NUTX Comparison
Compare ARVN & NUTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | NUTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.0M | 729.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARVN | NUTX |
|---|---|---|
| Price | $12.61 | $189.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 2 |
| Target Price | $17.80 | ★ $252.50 |
| AVG Volume (30 Days) | ★ 2.3M | 219.4K |
| Earning Date | 11-05-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 17.98 |
| Revenue | $312,300,000.00 | ★ $981,195,633.00 |
| Revenue This Year | $11.06 | $104.36 |
| Revenue Next Year | N/A | $4.10 |
| P/E Ratio | ★ N/A | $10.60 |
| Revenue Growth | 93.86 | ★ 236.03 |
| 52 Week Low | $5.90 | $28.12 |
| 52 Week High | $24.77 | $191.73 |
Technical Indicators
Market Signals| Indicator | ARVN | NUTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 71.16 |
| Support Level | $11.66 | $107.09 |
| Resistance Level | $13.56 | $187.20 |
| Average True Range (ATR) | 0.57 | 15.82 |
| MACD | 0.00 | 6.35 |
| Stochastic Oscillator | 61.43 | 98.28 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About NUTX Nutex Health Inc.
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.